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IL-17–producing CD8+ T (Tc17) cells are detectible in multiple sclerosis (MS) lesions; however, their contri-
bution to the disease is unknown. To identify functions of Tc17 cells, we induced EAE, a murine model of 
MS, in mice lacking IFN regulatory factor 4 (IRF4). IRF4-deficient mice failed to generate Tc17 and Th17 cells 
and were resistant to EAE. After adoptive transfer of WT CD8+ T cells and subsequent immunization for EAE 
induction in these mice, the CD8+ T cells developed a Tc17 phenotype in the periphery but could not infiltrate 
the CNS. Similarly, transfer of small numbers of WT CD4+ T cells alone did not evoke EAE, but when trans-
ferred together with CD8+ T cells, IL-17–producing CD4+ (Th17) T cells accumulated in the CNS and mice 
developed severe disease. Th17 accumulation and development of EAE required IL-17A production by CD8+ 
T cells, suggesting that Tc17 cells are required to promote CD4+ T cell–mediated induction of EAE. Accord-
ingly, patients with early-stage MS harbored a greater number of Tc17 cells in the cerebrospinal fluid than in 
peripheral blood. Our results reveal that Tc17 cells contribute to the initiation of CNS autoimmunity in mice 
and humans by supporting Th17 cell pathogenicity.
Introduction
Multiple sclerosis (MS) is an incurable inflammatory autoimmune 
disease of the CNS that affects several million people worldwide. 
The murine model of MS, EAE, can be induced by activation or 
adoptive transfer of CD4+ Th cells that recognize myelin anti-
gens and cross the blood-brain barrier. Activation of autoreactive 
Th cells is, therefore, believed to be important for the induction, 
maintenance, and regulation of inflammatory demyelination in 
EAE and MS (1). Several lines of evidence indicate that Th17 cells, 
which can produce IL-17A, IL-17F, IL-21, and IL-22, are involved 
in the onset and maintenance of EAE (2). Previously, we and others 
have described the essential role of IFN regulatory factor 4 (IRF4), 
a member of the IRF family of transcription factors (3, 4), for Th17 
cell differentiation and EAE (5–8).
Although CD8+ T cells are also present in MS lesions, their role 
in the disease is unclear (1). Conflicting evidence from studies 
of EAE suggests pathogenic (9, 10) or beneficial (11, 12) func-
tions of these cells. Recently, an IL-17–producing CD8+ T cell 
subpopulation, termed Tc17, was described in mice and humans 
(13–16). Compared with canonical CTLs, Tc17 cells exert many 
less cytotoxic effector functions, due to their greatly diminished 
levels of the T-box transcription factor Eomesodermin (Eomes), 
of IFN-γ, and of the cytolytic molecule granzyme B. Tc17 cells are 
detectable in MS lesions (17) and in the CNS and LNs of mice 
during EAE (16), but their function remained undefined.
In this study, we analyzed (a) molecular requirements for Tc17 
differentiation, (b) function of Tc17 cells during EAE, and (c) 
their presence in patients with early-stage MS. We show that 
IRF4 is pivotal for differentiation of Tc17 cells in vitro and in 
vivo during CNS autoimmunity. Using IRF4-deficient mice, we 
demonstrate a previously unknown cooperation of Tc17 and 
Th17 cells for the induction of EAE. The pathogenic interplay 
requires IL-17A but not CCR6 competence by CD8+ T cells and 
CCR6 but not IL-17A sufficiency by CD4+ T cells. Along with 
the in vivo data, we demonstrate a direct, cell contact–mediated 
helper activity of Tc17 cells for Th17 differentiation in vitro. 
Furthermore, increased numbers of Tc17 are detectable in cere-
brospinal fluid (CSF) from patients with early-stage MS, suggest-
ing their contribution to disease progression in humans.
Results
IRF4 governs Tc17 differentiation by balancing the levels of RORγt, 
Eomes, and Foxp3. As a prerequisite for our concept to use Irf4–/– 
mice in order to study the role of CD8+ T cells during EAE, we 
first analyzed the dependence of Tc17 differentiation on IRF4. 
Therefore, we primed CD8+ T cells from Irf4+/+ (WT) or Irf4–/– 
mice under conditions favoring CTL differentiation or with IL-6 
and TGF-β added alone or in combination (Tc17 condition) and 
found that IRF4 was mandatory for the development of Tc17 
cells, as determined by intracellular staining (Figure 1A). Con-
sistent with the defect in IL-17 production, the mRNA levels 
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for factors characteristic for Tc17 differentiation (14–16), such 
as RORγt (Rorc) and RORα (Rora) as well as the IL-23 receptor 
(Il23r) and the cytokine Il21, were strongly diminished in Irf4–/–
CD8+ T cells (Figure 1B). To analyze whether this block in Tc17 
differentiation was caused by defective induction of RORγt, we 
overexpressed RORγt in WT and Irf4–/–CD8+ T cells cultured 
under Tc17 conditions. Forced expression of RORγt led to 
strongly enhanced IL-17 production in WT cells and, albeit at a 
markedly lower level, also in Irf4–/– cells (Figure 1C). Thus, RORγt 
is necessary but not sufficient to restore the Tc17 phenotype in 
Irf4–/– cells and additional mechanisms, such as interplay with 
other transcription factors, are likely to be relevant.
Figure 1
Tc17 differentiation depends on IRF4. (A and F) Purified WT and Irf4–/–CD8+ T cells activated via CD3/28 plus cytokines as indicated were stained 
for IFN-γ, IL-17, or Foxp3. (B and D) mRNA expression of the indicated genes analyzed by quantitative real-time RT-PCR in Irf4–/– (black) or WT 
(white) CD8+ T cells. Data (± SD) represent PCR duplicates. (C and G) WT or Irf4–/–CD8+ T cells transduced with retroviruses expressing RORγt-
GFP (RORγt), Eomes-VP16-GFP (Eomes), Foxp3-Thy1.1 (Foxp3), or the control viruses MSCV-GFP (MIG) or MSCV-Thy1.1 (MIT) activated 
as indicated and stained for IL-17 or IFN-γ. Analyses were performed on a (C) GFP+ or (G) Thy1.1+GFP+ gate. (E) Western blot for Eomes and 
β-actin in WT and Irf4–/–CD8+ T cells after 72 hours of activation. (A, C, F, and G) Numbers represent percentages of positive cells. (A–G) Data 
are representative of 3 independent experiments.
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We and others have previously published that the amounts of 
the CTL-specific transcription factor Eomes (18) negatively cor-
related with Tc17 development (16, 19, 20). Notably, the expres-
sion of Eomes at the mRNA and protein level (Figure 1, D and E) 
was markedly enhanced in Irf4–/– cells as compared with that in 
WT CD8+ T cells, even under Tc17 conditions.
In CD4+ T cells, IL-6 acts as a switch factor between Th17 and 
Treg cells by upregulating RORγt and RORα and by suppressing 
TGF-β induced Foxp3 (2). When we tested Foxp3 expression, we 
found that, similar to CD4+ T cells (5), culture with TGF-β induced 
high Foxp3 expression in WT and Irf4–/–CD8+ T cells, whereas 
addition of IL-6 downregulated Foxp3 in WT but not Irf4–/–CD8+ 
T cells (Figure 1F).
Because the protein levels for Eomes and Foxp3 were upregulated 
in Irf4–/–CD8+ T cells (Figure 1, E and F), we examined whether 
enhanced expression of these transcription factors influences IL-17 
production. Therefore, WT CD8+ T cells were infected with viruses 
expressing Eomes-GFP and/or Foxp3-Thy1.1 and cultured under 
Tc17 conditions. Compared with infection with control viruses, 
forced expression of either Eomes or Foxp3 suppressed the frequen-
cies of IL-17–positive cells to a limited extent, while transduction 
with Eomes considerably increased the percentage of IFN-γ–posi-
tive cells, as expected (18). Coexpression of Eomes and Foxp3 led 
to an additive inhibition of IL-17 production (Figure 1G), while 
the high IFN-γ production induced by Eomes alone was not sig-
nificantly influenced by Foxp3 coexpression. The effects on the 
amounts of IL-17 and IFN-γ in doubly infected cells were then ana-
lyzed based on the relative intensities of GFP and Thy1.1 expression, 
representing the relative expression of Eomes and Foxp3, respec-
tively. Importantly, within the same culture reduction of IL-17 and 
enhancement of IFN-γ production, both correlated with the ratio 
of Eomes and Foxp3 expression (Supplemental Figure 1, A–C; sup-
plemental material available online with this article; doi:10.1172/
JCI63681DS1), strongly implying that Eomes and Foxp3 suppress 
IL-17 production cell-intrinsically in a quantitative manner. Thus, 
the increase of Eomes and Foxp3 expression in Irf4–/–CD8+ T cells, 
together with reduced amounts of RORγt and RORα, cumulatively 
contribute to impaired Irf4–/– Tc17 differentiation.
We confirmed the role of IRF4 during Tc17 differentiation also 
in WT CD8+ T cells after transient knockdown using siRNA. Along 
with reduction of IRF4 protein amounts (Supplemental Figure 
2A), nucleofection with IRF4-specific siRNA (IRF4si), but not 
control scrambled siRNA, substantially reduced expression of Rorc 
mRNA and frequencies of IL-17–producing cells (Supplemental 
Figure 2, B and C). Conversely, the expression of Eomes, IFN-γ, and 
Foxp3 was elevated. Together, these results point to a central role 
of IRF4 in balancing the levels of the transcription factors Eomes, 
Foxp3, and RORγt during Tc17 differentiation.
Contribution of IRF4 and Tc17 cells to the induction of EAE. To explore 
the IRF4 requirement for Tc17 differentiation in vivo, we used an 
EAE model characterized by the presence of Tc17 cells (16). WT 
but not Irf4–/– mice immunized with the myelin oligodendrocyte 
glycoprotein amino acids 37–50 (MOG37–50) peptide developed 
severe EAE (Figure 2A) accompanied by demyelination as well as 
prominent CNS infiltration with CD3+ and MAC3+ cells (Supple-
mental Figure 3A). Moreover, CD8+ T cells able to produce IL-17 
and/or IFN-γ were present in LNs and CNSs of diseased WT mice 
(Supplemental Figure 3B). In contrast, almost no cell infiltrates 
Figure 2
Tc17 cells do not migrate into the CNS 
in an IRF4-deficient environment. (A 
and B) Mean clinical scores (± SEM) 
of MOG37–50-induced EAE in WT mice 
(n = 4) and Irf4–/– mice (n = 4) (A) with-
out or (B) with transfer of congenic 107 
CD45.2–CD8+ WT T cells. (C) Absolute 
T cell number per CNS (endogenous 
or transferred, averages of pooled 
cells of 4 mice). (D) CD8+ gate of cells 
from LNs and spleens of Irf4–/– mice 
substituted with 107 CD45.2–CD8+ WT 
T cells stained for CD8, CD45.2, IL-17, 
or IFN-γ at day 19 after immunization. 
Numbers represent percentages of 
cells in the respective quadrant. (A–D) 
Data are representative of 6 indepen-
dent experiments.
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Figure 3
CD8+ T cells mutually interact with CD4+ T cells to induce EAE. (A) Mean EAE scores (± SEM) combining 2 independent experiments of 
MOG37–50-immunized Irf4–/– mice (n = 6) that received sorted congenic 2.5 × 106 CD45.1+CD44loCD8+ and/or 104 CD62LhiCD45.1+ 2D2 T cells. 
P values were calculated comparing the scores of Irf4–/– mice transferred with 2D2 cells alone or in combination with CD8+ T cells. (B and D) 
Absolute numbers in the CNSs of Irf4–/– mice of (B) T cells (mean ± SEM, n = 4) or (D) CD8+ T cells after transfer of 2D2 or CD8+ T cells alone 
or in combination. (C) Absolute numbers of CD8+ compared with CD4+ T cell numbers after cotransfer of 2D2 and CD8+ T cells. (C and D) 
Averages of pooled cells of 4 mice at day 15 after immunization. (E) Histology of spinal cords at day 15 after immunization. Immunochemically 
stained cells were detected as red-brown foci. Scale bar: 100 μm. KB, Klüver-Barrera. (F) Flow cytometry of gated CD4+ or CD8+ CNS cells 
after PMA/ionomycin restimulation. Numbers represent percentages of cells in the respective quadrant. (A–F) The experiments were repeated 
4 times with consistent results. *P < 0.05; ***P < 0.001.
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and no demyelination were found in the CNSs of Irf4–/– mice and 
the few CD8+ T cells barely produced cytokines (Supplemental Fig-
ure 3, A and B), while LNs contained only IFN-γ−producing CD8+ 
T cells but not Tc17 cells. Thus, despite being nonlymphopenic, 
Irf4–/– mice are characterized by loss of Tc17 differentiation and 
resistance to EAE after immunization with MOG37–50.
To analyze the contribution of WT CD8+ T cells to the pathogen-
esis of EAE, we transferred congenic WT CD45.2–CD8+ T cells into 
CD45.2+Irf4–/– or control CD45.2+ WT mice. This transfer had no 
substantial effect on the disease course or CNS pathology in WT 
mice (Figure 2B and Supplemental Figure 3A). Remarkably, Irf4–/– 
mice did not develop EAE or CNS pathology, even after transfer of 
WT CD8+ T cells (Supplemental Figure 3A). Consistent with clinical 
outcome, only negligible numbers of endogenous and transferred 
T cells were detectable in the CNSs of Irf4–/– mice (Figure 2C). In con-
trast, we found high numbers of transferred CD8+ T cells in lymphatic 
organs of Irf4–/– mice. Of these, a substantial fraction produced IL-17 
or IFN-γ (Figure 2D), while endogenous Irf4–/–CD8+ T cells again pro-
duced only IFN-γ, but not IL-17. Hence, WT CD8+ T cells differenti-
ate into Tc17 cells within Irf4–/– lymphatic organs after immunization 
with MOG37–50, but do not migrate into the CNS and are not suffi-
cient to cause autoimmune CNS inflammation.
CD8+ T cells help Th17 cells during induction of EAE. A previous 
report in a viral model described CD4+ T cell dependence of CD8+ 
T cell mobilization into infected tissue (21). Such a supportive 
CD4+ T cell component could be absent in Irf4–/– mice due to 
their defect in Th17 differentiation (5, 6). To determine whether 
antigen-specific help provided by IRF4-competent CD4+ T cells is 
required for migration of Tc17 cells into the CNS, we first trans-
ferred titrated numbers of either 2D2 T cells, which are transgenic 
for a MOG-specific Vβ11+ T cell antigen receptor (TCR) (22), or 
polyclonal naive CD4+ T cells and evaluated disease induction in 
Irf4–/– mice. For 2D2 cell transfers, we found that we were still at 
a saturating level (elucidated by disease outcome) with 105 cells. 
Because our aim was to analyze a contribution of CD8+ T cells 
to EAE development, we then applied subpathogenic numbers 
of the respective CD4+ T cells, which either failed to induce EAE 
(transfer of polyclonal CD4+ T cells; Supplemental Figure 4A) or 
caused delayed disease (transfer of 2D2 cells; Figure 3A). Due to 
the lower frequency of antigen specificity, we injected polyclonal 
CD8+ T cells at high numbers as compared with antigen-specific 
2D2 cells. Importantly, when subpathogenic numbers of 2D2 or 
WT CD4+ T cells were cotransferred with WT CD8+ T cells, the 
susceptibility of Irf4–/– mice to EAE was restored (Figure 3A and 
Figure 4
CD4+ T cells require CCR6 to cooperate with CD8+ T cells for infiltration into the CNS. (A) Mean clinical scores (± SEM) of MOG37–50-immunized 
Irf4–/– mice (n = 4) substituted with 107 WT CD45.2–CD8+ T plus 2.5 × 106 WT CD45.2+CD4+ T cells or Ccr6–/–CD45.2+CD4+ T cells. P values 
were calculated comparing the scores of Irf4–/– mice transferred with WT CD8+ T cells plus either WT CD4+ or Ccr6–/–CD4+ T cells. (B) qRT-PCR 
for Ccr6 mRNA in Irf4–/– (black) or WT (white) CD4+ T cells stimulated for 2 days as described. Data (± SD) of PCR duplicates. (C) Histology of 
spinal cords at day 26 after immunization: H&E staining (scale bar: 100 μm); immunochemically stained cells were detected as brown foci (scale 
bar: 50 μm). (A–C) The experiments were repeated twice with consistent results. **P < 0.005; ***P < 0.001.
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Supplemental Figure 4A), a finding accompanied by prominent 
T cell infiltration and pathology in the CNS (Figure 3, B–E, and 
Supplemental Figure 4, B–D). Notably, cotransfer of CD4+ cells 
licensed not only transferred but also endogenous Irf4–/–CD8+ cells 
to enter the CNS (Figure 3D).
Most surprisingly, however, cotransferred CD4+ T cells (injected 
at lower numbers) outnumbered by far the CD8+ T cells (injected at 
higher numbers) among the CNS-invading cell population (Figure 
3C and Supplemental Figure 4D). These findings were confirmed by 
histological analysis of spinal cord sections: mostly Vβ11+CD4+ 2D2 
T cells accompanied by MAC1+ cells infiltrated the CNSs of Irf4–/– 
mice after cotransfer of 2D2 and CD8+ T cells (Figure 3E). Further-
more, a high frequency of the transferred CD45.1+ WT 2D2 cells or 
the polyclonal CD45.1+ WT CD4+ T cells and a considerable fraction 
of the transferred CD45.1+ WT CD8+ cells in the CNSs of diseased 
Irf4–/– mice produced IL-17 (Figure 3F and Supplemental Figure 
4E). Together, these findings argue for a previously unappreciated 
help of CD8+ cells for Th17 cells to infiltrate the CNS and initiate 
EAE. In accordance with our data, CD8-deficient mice developed 
significantly milder EAE than WT mice (9). In further accordance, 
antibody-mediated depletion of CD8+ T cells in WT mice amelio-
rated disease severity, and conversely, injection of both CD8+ and 
CD4+ T cells into Rag1–/– mice evoked stronger disease as compared 
with single cells transfers (Supplemental Figure 5, A and B). 
Interestingly, when transferred at high numbers, CD4+ T cells were 
encephalitogenic by themselves, with kinetics, cytokine profile, and 
histopathology similar to that induced by cotransfer of low num-
bers of CD4+ T cells and CD8+ T cells (Supplemental Figure 6, A–D).
Th17 cells require CCR6 to cooperate with CD8+ T cells for infiltration 
into the CNS. The chemokine receptor CCR6 has been shown to 
be essential for the first wave of antigen-specific Th17 cell migra-
tion into the CNS and induction of autoimmune inflammation 
(23, 24). Therefore, we next tested whether CD4+ T cells require 
CCR6 to be able to cooperate with CD8+ T cells for infiltrating the 
CNS. In contrast to WT CD4+ T cells, cotransfer of Ccr6–/–CD4+ 
T cells and WT CD8+ T cells did not evoke EAE in Irf4–/– mice, and, 
accordingly, very low numbers of CD4+, CD8+, and MAC1+ cells 
infiltrated the CNS (Figure 4, A and C, and Supplemental Figure 
7C). However, ex vivo cytokine analyses demonstrated IL-17–pro-
ducing CD8+ and CD4+ T cells in the spleens of substituted Irf4–/– 
mice (Supplemental Figure 7, A and B), confirming their potential 
for type 17 differentiation in vivo. Consistent with the loss of the 
Th17 phenotype of Irf4–/–CD4+ T cells (5–7) and a recent publica-
tion (25), we confirmed that IRF4 is essential for CCR6 expression 
by CD4+ T cells (Figure 4B). Thus, IRF4-deficient CD4+ T cells, 
at least partially, can not mediate CD8+ T cell migration into the 
CNS due to their strongly diminished CCR6 expression.
In contrast to the disease induced by cooperating CD4+ and 
CD8+ T cells, high numbers of CD4+ T cells failed to require CCR6 
for the induction of disease, because transfer of Ccr6–/– or WT 
CD4+ T cells evoked similar disease course in Irf4–/– mice (Supple-
mental Figure 8, A–C). Accordingly, WT and Ccr6–/– mice devel-
oped similar disease course after immunization with MOG37–50 
(Supplemental Figure 8D). Thus, these data reveal 2 different ways 
to induce EAE: one requires CCR6 on CD4+ cells to cooperate with 
CD8+ T cells, while the other operates at high numbers of CD4+ 
T cells and acts independently of CCR6.
Th17 cell–derived IL-17A is not required for EAE induction by cooper-
ating CD8+ T cells and Th17 cells. Because high frequencies of IL-17–
producing CD4+ T cells infiltrated the CNSs of Irf4–/– mice after 
cotransfer of CD4+ and CD8+ T cells, we investigated whether the 
production of this Th17 signature cytokine by CD4+ T cells has 
an impact on disease development. Il17a–/–CD4+ T cells cooper-
ated with CD8+ T cells to the same extent as WT CD4+ cells for the 
Figure 5
IL-17A competence of CD4+ T cells 
is not required for their pathogenicity.  
(A) Mean clinical scores (± SEM) 
of MOG37–50-immunized Irf4–/– mice 
(n = 4) substituted with 2.5 × 106 WT 
CD4+ T cells or Il17a–/–CD4+ T cells 
with or without 107 WT CD8+ T cells. 
P values were calculated comparing the 
scores of Irf4–/– mice transferred with 
WT CD4+ T cells alone or WT CD8+ 
T cells plus Il17a–/–CD4+ cells. (B) Abso-
lute numbers of T cells (mean ± SEM, 
n = 4) in the CNSs of Irf4–/– mice after 
transfer of WT CD4+ T cells alone or of 
WT CD8+ T cells in combination with 
either WT CD4+ or Il17a–/–CD4+ T cells. 
(C) Flow cytometry of gated CD4+ CNS 
cells stained for IL-17A, IL-17F, or IFN-γ. 
Numbers represent percentages of 
cells in the respective quadrant. (A–C) 
The experiments were repeated twice 
with consistent results. *P < 0.05; 
**P < 0.005; ***P < 0.001.
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induction of EAE as determined by severe paralysis and massive 
T cell infiltration in the CNS (Figure 5, A and B). As anticipated, the 
CNS-invading WT but not the Il17a–/–CD4+ T cells were able to pro-
duce IL-17A, while both of them were positive for the other Th17-
marker cytokine, IL-17F (Figure 5C). Possibly due to compensatory 
mechanisms, Il17a–/–CD4+ T cells produced more IL-17F than their 
WT counterparts. Therefore, IL-17A produced by CD4+T cells is 
not required for the cooperation of CD4+ and CD8+ T cells during 
induction of EAE, probably because Il17a–/–CD4+ T cells invading 
the CNS still developed a Th17-like phenotype, as determined by 
their ability to produce IL-17F.
Committed Th17 cells do not require help of CD8+ T cells for their patho-
genicity. To evaluate whether CD8+ T cells influence the pathoge-
nicity of already committed Th17 cells, we transferred in vitro–
differentiated Th17 cells alone or in combination with CD8+ 
T cells. In contrast to uncommitted CD4+ T cells, low numbers of 
differentiated Th17 cells already induced disease in Irf4–/– mice by 
themselves, and cotransfer of CD8+ T cells failed to influence dis-
ease course and severity (Figure 6). These data suggest that CD8+ 
T cells enhance the pathogenicity of CD4+ cells during initiation of 
the disease by influencing Th17 phenotype development.
IL-17A but not CCR6 competence of CD8+ T cells promotes Th17 cell 
encephalitogenicity. According to the “2-waves hypothesis,” the flux 
of cells into the CNS during the second wave should be CCR6 inde-
pendent (23). To evaluate whether CD8+ T cell migration meets this 
criterion, we cotransferred 2D2 T cells and Ccr6–/–CD8+ T cells into 
Irf4–/– mice. Cotransfer of 2D2 and either WT or Ccr6–/–CD8+ T cells 
caused nearly identical onset of disease and CNS infiltration by 
T and MAC1+ cells (Figure 7, A and C). Thus, in contrast to CD4+ 
T cells, CCR6 expression by CD8+ T cells is not essential for induc-
tion of disease, suggesting that CD8+ T cells enter the CNS in the 
CCR6-independent second wave of autoimmune inflammation.
Next, we evaluated whether CD8+ T cells need IL-17A, and there-
fore belong to the Tc17 subset, to accelerate encephalitogenicity of 
CD4+ T cells. Strikingly, Il17a–/–CD8+ T cells did not provide help 
for the pathogenicity of 2D2 T cells, as shown by clinical onset of 
EAE and tissue infiltration by CD4+, CD8+, or MAC1+ cells (Figure 
7, B and C). To provide more direct evidence for the supportive 
role of Tc17 cells for Th17 pathogenicity, we performed cotrans-
fers of in vitro skewed WT and Il17a–/– Tc17 cells together with 
2D2 T cells. In agreement with data obtained with cotransfers of 
naive CD8+ T cells, WT but not Il17a–/– Tc17 cells cooperated with 
CD4+ T cells for EAE induction (Supplemental Figure 9, A and B). 
Consistent with clinical outcome, in the CNSs of diseased mice we 
found high numbers of T cells and the ratio of CD4+ to CD8+ T cell 
numbers was similar to that observed by cotransfer of naive CD8+ 
T cells (Supplemental Figure 9, C and D, and Figure 3C). CD4+ 
T cells were the dominating population characterized by strik-
ingly high IL-17 production (Supplemental Figure 9, D and E). As 
expected CNS-infiltrating CD8+ T cells produced high amounts 
of IL-17; however, in vivo they acquired additionally the ability to 
coproduce IFN-γ (Supplemental Figure 9E).
These data imply that IL-17A produced by Tc17 cells is 
required to render CD4+ cells more encephalitogenic and sup-
port the previously published idea of the importance of IL-17A 
during the initiation of EAE (26–28). Moreover, this result sug-
gests that the inability of Irf4–/–CD8+ T cells to potentiate the 
pathogenicity of CD4+ T cells is at least partially explained by 
their defective Tc17 differentiation.
Tc17 cells but not their supernatants trigger the Th17 differentiation pro-
gram. Given that WT but not Il17a–/– Tc17 cells provided help for 
stronger pathogenicity of Th17 cells, we investigated whether Tc17 
cells can directly promote Th17 differentiation in vitro. To this 
end, we cocultured WT or Il17a–/– Tc17 cells or their supernatants 
Figure 6
CD8+ T cells fail to accelerate pathogenicity of 
committed Th17 cells. (A) 2D2 cells were polarized 
under Th17 conditions in vitro for 3 days. There-
after, Irf4–/– mice (n = 4) were substituted with 
these cells either alone or in combination with WT 
2.5 × 106 CD44loCD8+ T cells and subsequently 
immunized with MOG37–50. Mean clinical scores 
(± SEM) are shown. (B) Absolute numbers 
of T cells (mean ± SEM, n = 4) in the CNSs of 
Irf4–/– mice after transfer of Th17 cells alone or in 
combination with CD44loCD8+ T cells. (C) Flow 
cytometry of transferred in vitro–differentiated 
2D2 cells polarized under Th17 conditions and of 
gated CD4+ CNS cells stained for IL-17A or IFN-γ. 
Numbers represent percentages of cells in the 
respective quadrant. (A–C) The experiments were 
repeated twice with consistent results. 
research article
254 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 1   January 2013
(SNs) with purified CD4+ T cells in the presence of anti-CD3/
CD28 stimulation. In order to directly verify the role of soluble 
IL-17A, exogenous recombinant murine IL-17A (rmIL-17A) was 
added to cocultures containing Il17a–/– Tc17 cells. After 3 days 
of coculture, CD4+ T cells were FACS sorted and either analyzed 
directly for their mRNA expression profiles or restimulated to 
assess cytokine production in the SNs.
Tc17 cells themselves, but neither their SNs nor rmIL-17A, 
induced the type 17 transcriptional program in CD4+ T cells. 
Surprisingly, the induction of Rorc, Il21, and Il23r mRNA was 
independent of the Tc17 cell capacity to produce IL-17A (Figure 
8A). In striking contrast, WT but not Il17a–/– Tc17 cells promoted 
expression of IL-17A itself in CD4+ T cells at the mRNA and pro-
tein level (Figure 8, A and B). To evaluate the possibility that SNs 
from Il17a–/– Tc17 cells possess any inhibitory activity on the 
IL-17A production by CD4+ T cells, we cocultured WT Tc17 cells 
with CD4+ T cells in the presence of SN from Il17a–/– Tc17 cells. 
However, Il17a–/– Tc17 cell SNs did not influence Tc17 cell–medi-
ated IL-17A production by CD4+ T cells (Supplemental Figure 10). 
Taken together, these results indicate that in vitro WT and Il17a–/– 
Tc17 cells support the Th17 differentiation program via direct cell 
contact. In contrast, IL-17A competence of Tc17 cells is required 
for production of IL-17A itself in CD4+ T cells.
An important control for these conclusions was that similar 
amounts of IL-17A had been present in the respective culture 
settings. Therefore, we confirmed that SNs harvested after the 
coculture period contained approximately similar quantities of 
IL-17A in wells with WT Tc17 cells or with Il17a–/– Tc17 cells plus 
exogenous IL-17A (Figure 8C). The highest amounts of IL-17A 
were detectible in control CD4+ T cultures containing exogenous 
IL-17A but no Tc17 cells, although this condition lacked IL-17A–
inducing activity (Figure 8B). These data suggest that the promo-
tion of IL-17A production in CD4+ T cells requires both direct 
contact and IL-17A competence by Tc17 cells.
Figure 7
IL-17A competence of CD8+ T cells accelerates CD4+ T cell encephalitogenicity. (A and B) Mean EAE scores (± SEM) combining 2 independent 
experiments of MOG37–50-immunized Irf4–/– (n = 6) mice that received sorted 2.5 × 106 CD44loCD8+ cells from WT, Ccr6–/–, or Il17a–/– mice and/
or 104 CD62Lhi 2D2 T cells. P values were calculated comparing (A) the scores of Irf4–/– mice transferred with 2D2 alone or 2D2 in combination 
with Ccr6–/–CD8+ T cells and (B) the scores of mice transferred with 2D2 T cells in combination with WT CD8+ T cells or in combination with 
Il17a–/–CD8+ T cells. (C) Histology of spinal cords at day 13 after immunization: Klüver-Barrera staining (scale bar: 100 μm); immunochemically 
stained cells were detected as brown foci (scale bar: 50 μm). (A–C) The experiments were repeated twice with consistent results. *P < 0.05; 
**P < 0.005; ***P < 0.001.
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Recently, it has been reported that Th17 cells express surface 
IL-17A (29). Similarly to Th17 cells, high frequencies of WT 
Tc17 cells expressed surface IL-17A (Figure 8D). In contrast, 
IL-17F was almost absent from the surface of these cells but 
was easily detectable intracellularly. As expected, Il17a–/– Tc17 
cells expressed IL-17A neither on the surface nor intracellularly. 
Probably, membrane IL-17A contributes to the promotion of 
IL-17 production by CD4+ T cells in a direct cell-cell interac-
Figure 8
Tc17 cells promote Th17 differentiation via direct cell contact in vitro. (A) Purified CD4+ T cells were mixed 1:1 with in vitro–differentiated WT or 
Il17a–/– Tc17 cells or their SNs with or without exogenous rmIL-17A and stimulated via CD3/CD28. After 72 hours, CD4+ T cells were sorted, and 
mRNA expression of the indicated genes was analyzed by qRT-PCR. Data (± SD) of PCR duplicates. (B) ELISA for IL-17A and IFN-γ produced by 
sorted CD4+ T cells after restimulation for 24 hours with anti-CD3. (C) ELISA for IL-17A in SNs of 72 hours cocultures as described for A. (B and 
C) Data (± SD) of ELISA duplicates. (D) WT or Il17a–/– Tc17 cells differentiated in vitro for 96 hours were restimulated with PMA/ionomycin in the 
presence or absence of brefeldin A and stained for IL-17A, IL-17F, and IFN-γ either on their surface (left) or intracellularly (ICS) after permeabili-
zation (right). Numbers represent percentages of cells in the respective quadrant. (A–D) Data are representative of two independent experiments.
research article
256 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 1   January 2013
tion, because Il17a–/– Tc17 cells lack this activity, even in the 
presence of exogenous soluble IL-17A. As (a) IL-17A compe-
tence by Tc17 cells is required for the onset of EAE and (b) their 
IL-17A competence is not required for induction of Th17 dif-
ferentiation in vitro, the EAE-promoting activity of Tc17 cells 
can not entirely be explained by their capacity to directly induce 
Th17 cell differentiation. Rather, they probably need IL-17A 
to act on the local environment, e.g., to increase production 
of innate cytokines that in turn may augment generation of 
pathogenic Th17 cells.
Tc17 cells in CSF and peripheral blood of patients with MS. To 
determine whether the findings reported above in the mouse 
EAE model are compatible with the human disease, we ana-
lyzed the presence of Tc17 cells in patients with MS. We 
included in our study 17 patients at an early-stage of MS (clin-
ical data are summarized in Supplemental Table 1), of which 
11 suffered from a clinically isolated syndrome suggestive for 
MS (CIS) and 6 from early MS (eMS). In contrast to the con-
trol group that suffered from noninfectious headache (con-
trol), patients with early-stage MS (CIS/eMS) had higher fre-
quencies of Tc17 cells within CD8+ T cells from CSF than from 
peripheral blood (Figure 9A). Furthermore, we found signifi-
cantly higher percentages of Tc17 cells in CSF of patients with 
early-stage MS compared with control patients (Figure 9B). In 
contrast, the frequencies of Tc17 cells in peripheral blood of 
control patients and patients with early-stage MS did not differ 
(Figure 9B). This finding demonstrates selective enrichment of 
Tc17 cells in the CSF of patients with early-stage MS, suggest-
ing that, also in humans, Tc17 cells contribute to the initiation 
of CNS autoimmunity.
Discussion
Previous reports have described the necessity of the transcrip-
tion factor IRF4 for the development of the CD4+ T cell subsets 
Th2 (30, 31), Th17 (5, 6, 8), and Treg (32). Here, we extend these 
studies to CD8+ T cells and show that IRF4 is also critical for 
Tc17 differentiation. These results combined with our previous 
data on CD4+ T cells (5, 6) point to the central role of IRF4 for 
type 17 differentiation.
Complementary to the results obtained in CD4+ T cells (5, 
6), we found increased levels of Foxp3 in Irf4–/–CD8+ T cells 
cultured under Tc17 conditions and demonstrated that Foxp3 
inhibits IL-17 production also in CD8+ T cells. Concomitantly, 
the amounts of Eomes were upregulated in Irf4–/–CD8+ T cells 
and Eomes inhibited IL-17 production in CD8+ T cells, in sup-
port of the previously proposed repression of the Tc17 program 
by a combination of Eomes and T-bet (13) and the recently 
published Eomes-mediated suppression of Th17 differentia-
tion by its direct binding to the Rorc and Il17a promoters (33). 
Together with greatly impaired levels of RORγt and RORα, our 
data point to the central role of IRF4 in CD8+ T cells in balanc-
ing the levels of transcription factors responsible for Tc17, Treg 
(34), and CTL differentiation.
In the absence of IRF4, Tc17 development is also abolished in 
vivo. We showed this in an EAE model in Irf4–/– mice, induced by 
immunization with the MOG37–50 peptide and characterized by the 
presence of Tc17 cells in the CNS (16). We found a lack of Tc17 
cells in these mice, which correlated with complete EAE resistance. 
Surprisingly, adoptive transfer of WT CD8+ T cells was not suffi-
cient to restore EAE susceptibility, although Tc17 development of 
the transferred cells was readily detectable in LNs and spleens of 
Irf4–/– mice. Thus, Tc17 development of WT CD8+ T cells occurs 
in an Irf4–/– environment, but differentiated Tc17 cells are not 
sufficient on their own to infiltrate the CNS; rather, they require 
support from an IRF4-competent environment. This situation was 
reminiscent of the reported need for CD4+ T cell help to mobilize 
CD8+ T lymphocytes to the site of a viral infection (21). Indeed, we 
show that cotransfer of CD8+ T cells and few CD4+ T cells, which 
by themselves induced either no or strongly delayed onset of dis-
ease, caused early onset of EAE in Irf4–/– mice, accompanied by 
presence of transferred CD8+ and CD4+ T cells in the CNS.
Apparently, endogenous Irf4–/–CD4+ T cells were unable to sup-
port CD8+ T cell CNS migration, demonstrating an essential role 
for IRF4 within both CD4+ and CD8+ T cells during onset of EAE. 
Within CD4+ T cells, a contribution of IRF4 is to regulate CCR6 
expression because Irf4–/–CD4+ T cells expressed diminished 
amounts of Ccr6 mRNA and Ccr6–/–CD4+ T cells were unable to 
Figure 9
Frequency of Tc17 cells in peripheral blood and CSF of control patients 
and patients with early-stage MS. (A and B) IL-17+ cells among gated 
CD8+ T cells from CSF and peripheral blood (PBMCs) obtained from 
patients with early-stage MS (CIS/eMS, n = 17) as well as from patients 
with noninfectious headache (control, n = 17). PBMC and CSF lym-
phocytes were restimulated with CytoStim human. Thereafter, the 
cells were stained for surface CD8 and then fixed, permeabilized, 
and stained for intracellular IL-17. The box plots depict the minimum 
and maximum values (whiskers) and the upper and lower quartiles 
(top and bottom edges of the box). The median is identified by a line 
inside the box. The length of the box represents the interquartile range. 
P values were calculated with Mann-Whitney U test.
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especially the Tc17 subset are a sufficient and necessary IL-17A 
source, at least in our EAE model of co-operating CD4+ and CD8+ 
T cells. Consistent with the importance of IL-17A during initia-
tion of autoimmunity, CD8+ T cells enhanced the pathogenicity 
of uncommitted CD4+ T cells, probably by enhancing their Th17 
phenotype, whereas they failed to influence EAE mediated by 
already in vitro committed Th17 cells.
CNS-invading IL-17A–deficient CD4+ T cells developed a similar 
Th17 phenotype to that of WT CD4+ T cells, because they pro-
duced IL-17F at even enhanced amounts. Apparently, these “Th17-
like” cells still kept their pathogenicity, because their effect was 
comparable to that of WT CD4+ T cells and because endogenous 
Irf4–/–CD4+ cells were unable to replace them, most likely due to 
their defect in the entire Th17 differentiation program. Together, 
these data support the idea that, during induction of EAE by coop-
erating CD4+ and CD8+ cells, IL-17A is mainly an effector molecule 
of CD8+ T cells, while in CD4+ T cells, it can be viewed as a marker 
of pathogenic Th17 cells (40). Nevertheless, IL-17A produced by 
CD4+ T cells may contribute to pathogenicity at later stages, e.g., 
by facilitating leukocyte trafficking across the blood-brain barrier 
and inflammation within the CNS (40).
To analyze whether Tc17 cells directly transmit signals that 
activate CD4+ T cells, we performed in vitro coculture assays. Our 
results demonstrate a cell contact–dependent but IL-17A–inde-
pendent interaction between Tc17 and CD4+ T cells that induces 
the Th17 transcriptional profile. In contrast, enhanced produc-
tion of IL-17A itself by CD4+ T cells required IL-17A competence 
of Tc17 cells, and this activity could not be replaced by exogenous 
soluble IL-17A. Probably, surface IL-17A expressed by Tc17 cells 
contributed to their IL-17A–inducing function during the direct 
CD4+/CD8+ T cell interaction. Surface IL-17A has been previously 
described on human and mouse CD4+ T cells isolated from the 
CNSs of EAE-diseased animals (29).
Because, for pathogenicity in vivo, IL-17A competence is required 
in CD8+ cells and specifically in Tc17 cells but not in CD4+ T cells, 
we suggest that besides the direct CD4+/CD8+ interaction, Tc17 
cells exert an additional IL-17A–dependent indirect effect to induce 
EAE. An amplifying function of IL-17A during Th17-mediated 
autoimmunity has been suggested before (26, 39) and was attrib-
uted to stimulation of innate immune cells to produce the Th17 
driving cytokines IL-1β, IL-6, or IL-23. We assume that during EAE, 
IL-17A–producing Tc17 cells promote pathogenicity of Th17 cells 
also via a similar indirect mechanism, e.g., by activating APCs.
Based on our data, we propose 2 sequential steps during EAE 
induction by cooperating CD4+ and CD8+ T cells. The first event 
is crucial to endow CD4+ T cells with stronger pathogenicity and 
requires direct cell contact among Tc17 cells, CD4+ T cells, and 
probably also APCs. During this initial process, Tc17 cells might 
promote directly and indirectly, via IL-17A–dependent APC activa-
tion, the differentiation of CD4+ T cells toward the pathogenic Th17 
phenotype and thus regulate the first wave of CD4+ cell migration 
into the CNS via CCR6 (23). These Th17 cells in turn facilitate the 
CCR6-independent migration of Tc17 cells in the second wave. The 
exact details of the in vivo cooperation between IL-17A–competent 
CD8+ T cells and CCR6-competent CD4+ T cells during autoim-
mune CNS inflammation deserve further exploration.
We think that the herein described support of Tc17 cells for the 
initiation of Th17-mediated disease uncovered by T cell transfers 
into Irf4–/– mice also applies to a WT situation. This reasoning is 
supported by several findings obtained by our group and others. 
cooperate with WT CD8+ T cells for encephalitogenicity. These 
features combined with the loss of the entire Th17 phenotype 
(5, 6) probably caused the defect of Irf4–/–CD4+ T cells to enable 
CD8+ T cell migration into the CNS. Thus, together with pre-
viously published data (23), our results argue for dependence 
of the CD8+ T cell recruitment into the CNS on a “first-wave” 
infiltration by CCR6- and IRF4-competent CD4+ T cells, while 
CD8+ T cells migrate in a second wave CCR6 independently. This 
concept is corroborated by our finding that CCR6 expression by 
CD8+ T cells was not necessary for their copathogenic function. 
Consistent with our results, the α4 integrin, a subunit of very 
late antigen-4 (VLA-4), has been defined as a major contributor 
of CD8+ T cell entry into CNS (35).
In contrast to the necessity for CCR6 expression by CD4+ 
T cells during cotransfer with CD8+ T cells, when applied at 
high numbers CD4+ T cells did not require CCR6 for induction 
of EAE in Irf4–/– mice. Moreover, Ccr6–/– mice developed a sim-
ilar disease course after immunization with MOG37–50 as com-
pared with WT controls. Thus, in our system, EAE induced by 
cooperating CD4+ and CD8+ T cells requires CCR6 expression 
by CD4+ T cells, in agreement with previous data (23), whereas 
EAE induced by high numbers of CD4+ T cells is CCR6 indepen-
dent. Apparently, CD4+ T cells can react to different conditions 
by using alternative mechanisms for CNS invasion, e.g., via the 
integrins α4 or αL (CD11a, a subunit of LFA-1), as suggested 
recently (36, 37). Importantly, however, this CCR6-independent 
invasion of CD4+ T cells operates only when they are available at 
high numbers. When translated to the situation in humans, such 
a high frequency of reactive CD4+ T cells presumably relates to a 
later stage of the disease when multiple events already occurred 
and a strong CD4+ T cell immunity exists. In contrast, the herein 
characterized cooperation of CD4+ and CD8+ T cells probably 
refers to the onset of the disease, when antigens for CD4+ cells 
are limiting but for CD8+ cells are present, particularly when the 
disease will be triggered by a viral infection.
Interestingly, cotransfer of small numbers of WT CD4+ T cells 
and high numbers of WT CD8+ T cells resulted in more CD4+ 
than CD8+ T cells detectable in the CNS. Because very low num-
bers of CD4+ T cells were found in the CNS after transfer of CD4+ 
T cells alone, our data suggest a previously not appreciated uncon-
ventional “reverse” help, namely of CD8+ T cells to support CNS 
infiltration by CD4+ T cells. We characterize the ability to produce 
IL-17A by CD8+ T cells as an important quality contributing to 
this help, because only IL-17A–competent naive CD8+ T cells 
or committed Tc17 cells accelerated CD4+ T cell pathogenicity, 
resulting in severe disease and accumulation of high numbers of 
IL-17–producing CD4+ T cells in the CNSs of EAE-diseased mice. 
Given that IL-17A was described as the hallmark of Tc17 cells, our 
results suggest that it is the Tc17 effector subset that accounts for 
the cooperation with CD4+ T cells.
The requirement for IL-17A–producing CD8+ T cells explains, 
at least in part, why endogenous Irf4–/–CD8+ cells were not able 
to enhance CD4+ T cell pathogenicity. The importance of IL-17A 
for initiation of autoimmunity has already been established (27, 
38, 39). Our study extends these previous reports by linking 
IL-17A production to CD8+ T cells and specifically to the Tc17 
subset in order to potentiate CD4+ T cell CNS pathogenicity. In 
contrast, IL-17A competence was not required for the CD4+ T cell 
part of this cooperation. Thus, the cellular origin of IL-17A is rel-
evant for pathogenicity. Our data suggest that CD8+ T cells and 
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lyzed by intracellular or surface staining, as described previously (30), on 
a FACSCalibur machine using the FlowJo software (Tree Star). Isotype 
staining revealed specificity of the IL-17 and IFN-γ stainings. For Foxp3 
detection, the Foxp3 Staining Kit (αFoxp3; FJK-16s; eBioscience) was used.
EAE induction and ex vivo flow cytometry. EAE was induced in sex- and age-
matched WT Irf4+/+ and Irf4–/– mice on the C57BL/6 background by subcu-
taneous injection of 200 μg MOG37–50 peptide (44) (VGWYRSPFSRVVHL; 
synthesized by R. Volkmer, Charité, Berlin, Germany) emulsified in CFA 
(containing 500 μg M. tuberculosis H37RA; Difco) together with i.p. admin-
istration of 200 ng pertussis toxin (Sigma-Aldrich) on days 0 and 2. Disease 
severity was scored daily on a scale of 0 to 5 (0, no paralysis; 1, limp tail; 
2, limp tail and partial hind leg paralysis; 3, complete hind leg paralysis; 4, 
tetraparesis; and 5, moribund). For transfer experiments, MACS-purified 
CD45.1+CD8+ T cells (107 per mouse) or CD62LhiCD4+ T cells (2.5 × 106 per 
mouse; CD45.1+, CD45.2+, CD45.2+Ccr6–/–, or CD45.2+Il17a–/–) isolated from 
naive donor mice were injected i.p. into recipients 1 day before immuniza-
tion. Alternatively, FACS-sorted CD44loCD8+ T cells (2.5 × 106 per mouse; 
CD45.1+, CD45.2+, CD45.2+Ccr6–/–, or CD45.2+Il17a–/–) or MACS-purified 
CD62LhiCD4+ T cells from 2D2 transgenic mice on the CD45.1+ or CD45.2+ 
background (low numbers, 104, or high numbers, 105 per mouse) isolated 
from naive donor mice were transferred i.p. into Irf4–/– recipients 1 day before 
immunization. For CD4+ and CD8+ T cell depletion, WT mice were injected 
i.p. twice, on days 3 and 6 after immunization with 300 μg monoclonal anti-
body against CD4 (clone YTS191) or CD8 (clone YTS169) or control immu-
noglobulin (rat IgG). The preparation of LN cells, splenocytes, and CNS 
lymphocytes was performed as previously described (5). CNS cells (pooled 
from the mice of one group or analyzed for each mouse individually), LN 
cells, or spleen cells (analyzed for each mouse individually) were restimu-
lated in vitro with 50 ng/ml PMA and 1 μg/ml ionomycin for 4 hours in the 
presence of 5 μg/ml brefeldin A. Viable cells (LIVE/DEAD Fixable Aqua Dead 
Cell Stain; Invitrogen) were analyzed for surface expression of CD8a (53–6.7; 
eBioscience), CD4 (RM4-5; Biolegend), CD45.2 (clone 104; BD), or CD45.1 
(A20; eBioscience). After fixation/permeabilization, cells were stained for 
IL-17A, IL-17F, and IFN-γ or with the respective isotype controls. Data 
were acquired with an LSRII, AriaIII, or FACSCalibur (BD Biosciences) and 
analyzed with the FlowJo software. Cell sorting was performed on a MoFlo 
(Beckman-Coulter) using the Summit-software (DakoCytomation).
Human PBMCs, staining, and FACS analysis. PBMCs were isolated from 
peripheral blood (on Ficoll-1077 density; Biochrom), and CSF leukocytes 
were collected after centrifugation; then these cells were restimulated for 6 
hours with CytoStim human (Miltenyi Biotech). After 2 hours of stimula-
tion, brefeldin A was added for the next 4 hours. Thereafter, the cells were 
stained for surface CD8 (SK1, BD Pharmingen), and then fixed, permea-
bilized, and stained for IL-17A (clone CZ8-23G1) using the Inside Stain 
Kit (both from Miltenyi Biotech). Staining procedures were performed as 
described previously (45). Data were acquired with a FACSCalibur machine 
and analyzed with CellQuest software.
Quantitative real-time PCR. Total RNA was extracted from CD8+ or CD4+ 
T cells at day 2 of priming or after FACS sorting from CD4+ cells at day 3 of 
coculture with Tc17 cells. For RNA isolation, the High Pure RNA Isolation 
Kit (Roche) was used. cDNA was synthesized with oligo(dT) primers using 
the RevertAid First-Strand cDNA Synthesis Kit (MBI Fermentas), and gene 
expression was examined with an ABI Prism 7500 Sequence Detection Sys-
tem (Applied Biosystems) using the SYBR Green I qPCR Core Kit (Euro-
gentec). Levels of each gene were normalized to hypoxanthine-guanine 
phosphoribosyl transferase (Hprt1) expression, and relative fold differences 
were calculated. The lowest experimental value was set to 1. The primer 
sets have been described previously (6, 16, 27). The following primer pair 
for Ccr6 was used: forward, 5′-TCCATCATCATCTCAAGCCCTAC-3′, and 
reverse, 5′-CGTGATGGGCTCTGAGACAGA-3′.
First, CD8+ T cell–deficient mice develop significantly milder EAE 
as compared with WT controls (9). Accordingly, we found that anti-
body-mediated depletion of CD8+ T cells also ameliorates disease 
severity. Second, even in the lymphopenic Rag1–/– environment, 
which is associated with homeostatic proliferation of transferred 
cells, CD8+ T cells significantly enhanced CD4+-mediated EAE. 
Probably because of the homeostatic proliferation and therefore 
increased activation, already low numbers of CD4+ T cells caused 
paralysis in Rag1–/– mice, in contrast to experiments performed in 
Irf4–/– mice, suggesting that the nonlymphopenic Irf4–/– environ-
ment is a better model for studying the influence of transferred 
T cells for initiation of EAE. Furthermore, we found under in vitro 
conditions, which are independent of the genetic environment, a 
supportive function of Tc17 cells for Th17 differentiation. In this 
setting, Tc17 cells via cell-cell contact directly provided help for the 
development of the type 17 transcriptional profile in CD4+ T cells 
and for the production of the cytokine IL-17A, which is associated 
with EAE severity. Finally, and most importantly for human MS, 
previous reports have already demonstrated the presence of Tc17 
cells in the lesions of patients with MS (17). Herein, we found 
enrichment in Tc17 cell frequencies in the CSF of patients with 
early-stage MS. This indicates that, also in humans, Tc17 cells are 
involved in the initiation of disease, perhaps when a cooperation 
of Tc17 and Th17 cells in the periphery has already occurred and 
Tc17 cells start to enter the CNS. This finding also suggests selective 
expansion and CNS recruitment of Tc17 cells in early-stage MS and 
that targeting of Tc17 cells may be of relevance for therapy in eMS.
Methods
Mice. WT C57BL/6 mice were purchased from The Jackson Laboratory. 
Irf4–/–, Ccr6–/– (41), Rag1–/–, 2D2 mice expressing a transgenic TCR specific for 
MOG35–55 (22), and CD45.1+ mice on the C57BL/6 background were bred at 
the animal facility of the Biomedical Research Center, University of Marburg. 
Il17a–/– mice were provided by Y. Iwakura, Center for Experimental Medi-
cine and Systems Biology, Institute of Medical Science, University of Tokyo, 
Tokyo, Japan. All mouse experiments were approved by the local government.
Patients. Patients included persons with CIS (n = 11, 64.7%) and with eMS 
(n = 6, 35.3%). None of the patients received any immunosuppressant or 
immunomodulation drug therapy prior to bio-sampling. They all suffered 
from their first clinical demyelinating attack and were diagnosed according 
to the McDonald criteria (42). Patients lacking prove of dissemination in 
time were classified as CIS (43); those who showed concurrent dissemina-
tion in space and time were classified as eMS. An additional 17 patients with 
noninfectious headache who underwent diagnostic lumbar puncture were 
included as controls. None of the latter had any symptoms or signs of sys-
temic infection. They all were otherwise healthy. The clinical characteristics 
of patients and their controls are summarized in Supplemental Table 1.
T cell purification, in vitro stimulation, and fluorescence staining. CD8+ or CD4+ 
T cells were purified by negative magnetic cell sorting (MACS, Miltenyi Bio-
tech) from spleens and LNs of 8- to 12-week-old mice and primed with plate-
bound αCD3 (3 μg/ml; clone 145-2C11) and soluble αCD28 mAb (0.5 μg/ml; 
clone 37.51) in the presence of recombinant human IL-2 (50 U/ml; 
Novartis), and αIFN-γ (5 μg/ml, clone XMG1.2) (CTL conditions). Some 
cultures received in addition 0.5 ng/ml recombinant human TGF-β1 
(R&D Systems), 20 ng/ml rmIL-6 (Peprotech), or combinations of these 
stimuli (Tc17 conditions). 72 hours later, cells were restimulated with 
50 ng/ml PMA and 1 μg/ml ionomycin in the presence or absence of 5 μg/ml 
brefeldin A (all from Sigma-Aldrich) for 4 hours, after which IL-17A–, 
IL-17F– and IFN-γ–producing cells (αIL-17A, clone eBio17B7; αIL-17F, 
clone eBio18F10; αIFN-γ clone XMG1.2; all from eBioscience) were ana-
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generate Tc17-conditioned SNs. Purified CD4+ T cells (5 × 105) were mixed 
1:1 with differentiated WT or Il17a–/– Tc17 cells or their SNs (final dilu-
tion: 30%) and stimulated with immobilized αCD3 (1 μg/ml) and soluble 
αCD28 (5 μg/ml) in 1 ml volume. Exogenous rmIL-17A (100 ng/ml) was 
added to some cocultures. After 72 hours of coculture, IL-17 concentra-
tions were determined by ELISA (R&D), and CD4+ T cells were separated 
from the Tc17 cells by flow cytometric cell sorting (>98.5% purity) using an 
AriaIII (BD Biosciences) and processed for mRNA purification or restimu-
lated with plate-bound αCD3 mAb (5 μg/ml). Culture SNs were analyzed 
by ELISA (R&D Systems).
Statistics. For clinical scores, differences between groups were evaluated by 
2-way ANOVA test with Bonferroni’s post-hoc test. For cell numbers in the 
CNS, differences between 2 cell populations were evaluated by 2-tailed Stu-
dent’s t test. The differences between patients with CIS/eMS and control 
patients were evaluated using 2-sided Mann-Whitney U test. Calculations 
were performed using GraphPad Prism software (GraphPad Software Inc.). 
P values of less than 0.05 were considered significant.
Study approval. All patients and controls gave their written informed con-
sent after the University of Marburg IRB approval (no. 126/00) for these 
experiments. Animal experiments were approved by the local committees 
(RP Gießen and TLLV Bad Langensalza, Germany).
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Nucleofection. WT CD8+ T cells were nucleofected immediately after puri-
fication with or without IRF4si or scrambled siRNA preparations. These 
siRNAs were prepared by IBA. Their sequences were previously described 
(5). Nucleofection of 107 cells in 100 μl of mouse T cell Nucleofector solu-
tion (Amaxa) was performed using 500 pMol total of siRNAs and the 
W001 program of the Nucleofector II machine (Amaxa). The nucleofected 
cells were primed under Tc17 conditions. The cells were harvested after 48 
hours for mRNA preparation and after 72 hours for intracellular staining 
of Foxp3, IL-17, and IFN-γ.
Immunoblotting. For the IRF4 immunoblots, whole cell lysates were pre-
pared after 1 day of in vitro stimulation, and for Eomes immunoblots, 
whole cell lysates were prepared after 3 days of in vitro stimulation. Immu-
noblotting was performed as described previously (6). Briefly, proteins 
were fractionated by SDS/PAGE, transferred to nitrocellulose membrane, 
immunoblotted with anti-IRF4 (M-17; sc6059; Santa Cruz Biotechnology) 
or anti-TBR2/Eomes (ab23345; Abcam) antibodies, and reprobed with 
antibodies to β-actin (A2066; Sigma-Aldrich).
Retroviral transduction. The retroviral vector pMSCV containing Eomes-
VP16-IRES-GFP (46) (Eomes) and the empty control vector containing 
IRES-GFP (MIG) were a gift from S.L. Reiner (University of Pennsylva-
nia, Philadelphia, Pennsylvania, USA). The retroviral vectors containing 
Foxp3 and RORγt have been described previously (6). The gene encoding 
Foxp3 (GenBank accession no. NM_054039.1) was amplified by PCR using 
published primers (47), control sequenced, digested by NotI and SalI, and 
cloned into the retroviral vector MSCV-IRES-Thy1.1 (gift from V. Heiss-
meyer, GSF-Institute of Molecular Immunology, Munich, Germany) con-
taining the internal ribosome entry site–regulated (IRES-regulated) gene 
for mouse Thy1.1. WT or Irf4–/–CD8+ T cells were infected with the retrovi-
ruses as described previously (6, 16) and stimulated via CD3/28 under the 
conditions indicated in the experiments. On day 3, the cells were restimu-
lated with PMA/ionomycin and then analyzed for GFP, Thy1.1, IL-17, and 
IFN-γ expression by flow cytometry.
Histological analysis. Histology of spinal cords was performed on serial 
sections (3 μm) from paraffin-embedded — or from cryostat — sections 
(10 μm) of shock frozen tissue, as described previously (48). Antibodies 
against MAC1 (M1/70, a gift from M. Simon, MPI, Freiburg, Germany), 
CD4 (RM4-5; BD), Vβ11 (RR3-15; BD), and CD8a (53-6.7; BD) for cryostat 
sections and CD3 (CD3-12AbD; Serotec) and MAC3 (M3/84; BD) for par-
affin sections were detected with biotinylated goat anti-rat IgG (Southern 
Biotechnology) and visualized with the Vectastain Kit (Vector Laboratories). 
Furthermore, H&E or Klüver-Barrera stainings were performed.
Coculture experiments. CD8+ T cells from WT or Il17a–/– mice were differ-
entiated under Tc17 conditions for 96 hours as described above, some of 
them were restimulated for 24 hours with immobilized αCD3 (5 μg/ml) to 
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